Skip to main content

Exjade and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Exjade (deferasirox).

Moderate

Caffeine Deferasirox

Moderate Drug Interaction

MONITOR: Coadministration with deferasirox may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 1A2 activity by deferasirox. In a study of healthy volunteers, administration of the CYP450 1A2 substrate theophylline (120 mg single dose) in combination with deferasirox (repeated dosing of 30 mg/kg/day) resulted in an approximate doubling of theophylline systemic exposure (AUC) and elimination half-life.

MANAGEMENT: Caution is advised if deferasirox must be used concurrently with medications that undergo metabolism by CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Moderate

Deferasirox Food

Moderate Food Interaction

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Exjade drug interactions

There are 584 drug interactions with Exjade (deferasirox).

Exjade disease interactions

There are 6 disease interactions with Exjade (deferasirox) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer